Bone marrow cellularity and percentage of normal B cells and CLL cells on ibrutinib
| . | Cellularity, % . | CLL cells of total lymphocytes, % . | Normal B cells of total lymphocytes, % . |
|---|---|---|---|
| Pretreatment | |||
| Patients | n = 69 | n = 13 | n = 13 |
| Median (min-max) | 75 (30-100) | 95 (19-99) | 0.00* (0-1.49) |
| 12 mo | |||
| Patients | n = 55 | n = 30 | n = 29 |
| Median (min-max) | 45 (5-90) | 68 (17-97) | 0.33* (0-8.19) |
| 24 mo | |||
| Patients | n = 38 | n = 58 | n = 35 |
| Median (min-max) | 50 (15-80) | 58 (2-97) | 0.54* (0-17.93) |
| . | Cellularity, % . | CLL cells of total lymphocytes, % . | Normal B cells of total lymphocytes, % . |
|---|---|---|---|
| Pretreatment | |||
| Patients | n = 69 | n = 13 | n = 13 |
| Median (min-max) | 75 (30-100) | 95 (19-99) | 0.00* (0-1.49) |
| 12 mo | |||
| Patients | n = 55 | n = 30 | n = 29 |
| Median (min-max) | 45 (5-90) | 68 (17-97) | 0.33* (0-8.19) |
| 24 mo | |||
| Patients | n = 38 | n = 58 | n = 35 |
| Median (min-max) | 50 (15-80) | 58 (2-97) | 0.54* (0-17.93) |
P = .01 and .002 in an unpaired Wilcoxon analysis comparing normal B cells at pretreatment to 12 and 24 mo, respectively.